Navigation Links
PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy

al data, we plan to initiate longer-term clinical trials to evaluate the clinical benefit of PTC124 in patients with DMD."

The Phase 2 clinical trial is being conducted at three sites in the United States: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; and the University of Utah, Salt Lake City, Utah. In the study, patients have received 28 days of PTC124 treatment at one of three dose levels. All clinical trial participants are boys with a nonsense mutation in the dystrophin gene, substantially elevated serum creatine kinase levels, and symptoms associated with DMD. The analysis presented today includes data from 26 patients with DMD who received PTC124 at the low-dose and medium-dose levels. Completion of accrual and analysis of data from a higher dose level are ongoing.

The primary endpoint of the trial has been the proportion of patients having an increase in dystrophin expression in muscle during 28 days of treatment with PTC124. Pre- and post-treatment muscle biopsies were available from all 26 patients for analysis. In vitro treatment of patient muscle cells with PTC124 showed evidence of a dose-dependent increase in dystrophin expression in all of the evaluable patients. Preliminary review of the data indicate that, at both dose levels evaluated in this analysis, approximately half of the patients demonstrated visible improvement in the staining for muscle dystrophin in vivo. Overall, four of the six, or 67 percent, of patients treated at the lower dose level and 10 of the 20, or 50 percent, of patients treated at the medium dose level demonstrated an increase in the expression of dystrophin post-treatment. Response did not appear to be dependent on type of nonsense mutation.

Additionally, statistically significant reductions in the concentrations of muscle-derived creatine kinase levels in the blood were observed during PTC124 treatment. Several parents a
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:5/22/2015)... , May 22, 2015 Electrophysiologist Kevin ... recently traveled to Boston, MA ... the 2015 Heart Rhythm Society conference. These scientific ... focus on the ideas, people and technology that ... is a hybrid, minimally invasive cardiac operation that ...
(Date:5/22/2015)... 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a ... and regeneration, today announced that J.J. Finkelstein , ... a corporate overview at two upcoming investor conferences. ... 4 th Annual Microcap Conference on Thursday May ... at 11:00 am EDT.  A webcast will be ...
(Date:5/22/2015)... May 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... peer-reviewed publication of the results of the Company,s ... preservative-free eye drops) for the treatment of dry ... (CAE ® ) model.  The exploratory study was ... were previously disseminated by the Company in a ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
... 22, 2011 Terso Solutions, Inc. has expanded its ... new refrigerator that is well-suited for hospital and ... the new refrigerator makes better use of space, reduces ... products such as reagents, cardiovascular products, tissue samples, and ...
... U.S. Food and Drug Administration today announced that Terumo ... two of its officers, Mark A. Sutter, president and ... Quality Assurance and Operations, have signed a consent decree ... ) The consent decree, to be ...
Cached Medicine Technology:Terso Solutions Launches New RFID-Enabled Refrigerator for Hospital and Laboratory Inventory Management 2FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree 2FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree 3
(Date:5/25/2015)... New York, New York (PRWEB) May 25, 2015 ... ( http://www.consumerinjurylawyers.com/depuy-pinnacle/lawsuit ) continue to move forward in ... District Court, Northern District of Texas. According to ... have asked the Court to modify the Case ... Disclose Health Information. Among other things, the Motion ...
(Date:5/25/2015)... White Plains, NY (PRWEB) May 25, 2015 ... LEED AP, principal of PBDW Architects in New York City, ... which is part of the hospital’s ongoing Legacy Lobby Lecture ... campus in White Plains. White is the great grandson of ... firm responsible for the design of Burke’s campus 100 years ...
(Date:5/24/2015)... Dallas, TX (PRWEB) May 24, 2015 ... the Global and Chinese Enterokinase Industry, 2009-2019 Market Research ... as it is an exhaustive study on the present ... a special insight into the growing Chinese market of ... market and the overall status of the manufacturers in ...
(Date:5/24/2015)... ProPin is a set of self-animating ... Utilize ProPin to pin point locations on a map, to ... , ProPin allows users to choose from 30 simplistic presets with ... on-screen controls, video editors can easily manipulate ProPin presets as a ... with absolute ease. , Using ProPin is easy, simply drag a ...
(Date:5/23/2015)... City, FL (PRWEB) May 23, 2015 On ... to build a new playground for Branches Florida City exactly ... the former play space in 2010. , A large fire ... new playground on May 23, 2010 in the middle of ... watched. The fire was later declared arson even though it ...
Breaking Medicine News(10 mins):Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 3Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 2Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Five Years After Fire, Branches Rebuilds Playground 2
... The FDA approved Tibotec,Pharmaceutical,s novel non-nucleoside ... announced introductory pricing for,the eagerly anticipated new ... other recently introduced antiretrovirals., "The efficacy ... DUET,studies is impressive. INTELENCE is an important ...
... Protects Sensitive Customer Health Care ... Data on Laptops and ... a global,leader in enterprise data protection, today announced that Payformance,Health, ... Electronic Funds Transfer (EFT) and Electronic Remittance,Advice (ERA) services, has ...
... reveals Boomers feel young, but often ignore important, health issues; company ... ... ST. LOUIS, Jan. 31 Baby boomers are living,longer and leading ... it comes to long-term health. According to a,recent survey by Energizer Holdings, ...
... ... -- Revises 2008 EPS Guidance Primarily to Reflect the Sale of Medical ... Imaging, -- Reaffirms Expected Non-GAAP EPS CAGR of at ... Through 2010, Subject to Certain Assumptions, -- Completes Sale of Medical Imaging Business, Reports as Discontinued, ...
... PARK CITY, Utah, Jan. 31 Nutraceutical,International Corporation (Nasdaq: ... first quarter ended December 31, 2007. Net sales for ... $35.8 million for the,same quarter of fiscal 2007. For ... million, or $0.28 diluted earnings per share, compared to,net ...
... Canadian Regulatory Authorities Approve 3f(R) Aortic Bioprosthesis for Sale ... ... Company Updates Financial Outlook for 2008, MINNEAPOLIS, Jan. 31 ... products and services, today announced it has received a request,for additional information and ...
Cached Medicine News:Health News:Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE 2Health News:Health Care Solutions Provider Payformance Health Standardizes on PGP Encryption for Data Security 2Health News:Health Care Solutions Provider Payformance Health Standardizes on PGP Encryption for Data Security 3Health News:Health Care Solutions Provider Payformance Health Standardizes on PGP Encryption for Data Security 4Health News:Boomers: Feeling Young or Fooling Themselves? 2Health News:Boomers: Feeling Young or Fooling Themselves? 3Health News:Boomers: Feeling Young or Fooling Themselves? 4Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 2Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 3Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 4Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 5Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 6Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 7Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 8Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 9Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 10Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 11Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 12Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 13Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 14Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 15Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 16Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 17Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 18Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 19Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 20Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 21Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 22Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 23Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 24Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 25Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 26Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 27Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 28Health News:Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007 29
Full Handle Laseredge Stab Blade Knife, 22.5 blade. Blade tip dimension: 10.7 mm x 1.8 mm x 4.2 mm....
18 gauge tapered fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Set consist of two 27 gauge, stainless steel probes with blunt tips. Probes are 11.5 cm (4.5 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto th...
Curved, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tubi...
Medicine Products: